At RSNA 2013, GE Healthcare introduced the Discovery Interventional Guidance System (IGS) 740, a 510(k)-pending mobile X-ray angiography system with a 41 x 41 cm detector. The system is aimed at interventional radiology market. 

BioCardia Inc., a cardiovascular regenerative medicine company, announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT).

Thomas Jefferson University researchers discovered that the formation of blood clots follows a different molecular route in African Americans versus European Americans, providing a new understanding of the effects of race on heart disease.

TherOx Inc. released results from the company's multicenter Investigational Device Exemption (IDE) pilot study that showed a 9.6 percent infarct size at 30 days in high-risk patients treated with its next-generation system for Supersaturated Oxygen (SSO2) Therapy. This therapy is intended to provide interventional cardiologists with the first treatment option beyond percutaneous coronary intervention (PCI) to salvage heart muscle in heart attack patients. The study results were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Toshiba introduced its Adaptive Diagnostics computed tomography (CT) technology, which simplifies complex exams, lowers dose and improves diagnostic accuracy and reproducibility, at the Radiological Society of North America Annual Meeting (RSNA 2013).

Watchman, LAA occluder, atrial fibrillation

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee voted favorably Dec. 11 in a 13-1 vote that the benefits of the Watchman Left Atrial Appendage Closure (LAA) device outweigh the risks. The company expects a decision from the FDA in the first half of 2014.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now